Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

30.61 +1.46 (+5.01%)
Streaming Delayed Price Updated: 3:44 PM EST, Jan 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck ↗
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
News headline image
A Better Switch ↗
Today the US market decided to rise because President Biden is pondering not linking his infrastructure project to a corporate tax increase. 
Via Talk Markets
News headline image
Alkermes Shares Move Higher On FDA Approval Of Schizophrenia, Bipolar Med ↗
The FDA has approved Alkermes plc's (NASDAQ: ALKS) Lybalvi, a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic... 
Via Benzinga
News headline image
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
News headline image
Why Shares of Alkermes Rose 18% Last Month ↗
An agreement with an activist investor capped a busy month. 
Via The Motley Fool
News headline image
Want to Make Money in Biotech? Do This First ↗
Keeping track of upcoming events is important. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
News headline image
Alkermes PLC (ALKS) Q1 2021 Earnings Call Transcript ↗
ALKS earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Alkermes: Q1 Earnings Insights ↗
Shares of Alkermes (NASDAQ:ALKS) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 1000.00% year over year to $0.11,... 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) Aldeyra Therapeutics, Inc... 
Via Benzinga
News headline image
Alkermes Launches Mid-Stage Melanoma Study Of Nemvaleukin As Monotherapy ↗
Alkermes plc (NASDAQ: ALKS) has initiated a Phase 2 trial, ARTISTRY-6, evaluating nemvaleukin alfa (nemvaleukin) monotherapy in patients with melanoma... 
Via Benzinga
News headline image
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx ↗
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
News headline image
The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 6) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.